{ "source": "Nasdaq Nordic Company News", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "status": "retrieved", "company": "XSpray Pharma", "reports": [ { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:00Z", "company": "XSpray Pharma AB", "title": "Xspray Pharma delårsrapport andra kvartalet 2026", "category": "Halvårsrapport", "date": "2026-08-05", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q2", "period": "2026-q2", "report_key": "2026:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bb97dea85ddf5e0ff88f534513012a6ab&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q2\\release.txt", "attachments": [ { "label": "Xspray Pharma delarsrapport Q2 2026.pdf", "url": "https://attachment.news.eu.nasdaq.com/a5fb4d9921ffc8f338e9eaa7b76e42b81", "final_url": "https://attachment.news.eu.nasdaq.com/a5fb4d9921ffc8f338e9eaa7b76e42b81", "filename": "Xspray_Pharma_delarsrapport_Q2_2026.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q2\\Xspray_Pharma_delarsrapport_Q2_2026.pdf", "content_type": "application/pdf", "size": 550185, "sha256": "02f3f4381a8341b276240e25960e35d4230f48dc2aae298f92712946fc4ef5a6", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q2\\Xspray_Pharma_delarsrapport_Q2_2026.pdf", "filename": "Xspray_Pharma_delarsrapport_Q2_2026.pdf", "extension": ".pdf", "size": 550185, "sha256": "02f3f4381a8341b276240e25960e35d4230f48dc2aae298f92712946fc4ef5a6", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q2\\extracted\\Xspray_Pharma_delarsrapport_Q2_2026\\Xspray_Pharma_delarsrapport_Q2_2026.txt", "text_chars": 47343, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q2\\extracted\\Xspray_Pharma_delarsrapport_Q2_2026\\Xspray_Pharma_delarsrapport_Q2_2026.extraction.json" } } ], "announcement_id": "1456862", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:03Z", "company": "XSpray Pharma AB", "title": "Delårsrapport första kvartalet 2026", "category": "Interimsrapport", "date": "2026-04-28", "language": "sv", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "period": "2026-q1", "report_key": "2026:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b6b31ffd7db671f2853e808cbe9a72b56&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q1\\release.txt", "attachments": [ { "label": "20260428 Xspray Pharma Q1 2026 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/afbf18fcb4e6880f16937b1dc4ce42b76", "final_url": "https://attachment.news.eu.nasdaq.com/afbf18fcb4e6880f16937b1dc4ce42b76", "filename": "20260428_Xspray_Pharma_Q1_2026_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q1\\20260428_Xspray_Pharma_Q1_2026_SWE.pdf", "content_type": "application/pdf", "size": 475147, "sha256": "6354e9b871d541856b0eba87fe93ab69eebd9278f587c7992d5501d2c03976fb", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q1\\20260428_Xspray_Pharma_Q1_2026_SWE.pdf", "filename": "20260428_Xspray_Pharma_Q1_2026_SWE.pdf", "extension": ".pdf", "size": 475147, "sha256": "6354e9b871d541856b0eba87fe93ab69eebd9278f587c7992d5501d2c03976fb", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q1\\extracted\\20260428_Xspray_Pharma_Q1_2026_SWE\\20260428_Xspray_Pharma_Q1_2026_SWE.txt", "text_chars": 40730, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2026-q1\\extracted\\20260428_Xspray_Pharma_Q1_2026_SWE\\20260428_Xspray_Pharma_Q1_2026_SWE.extraction.json" } } ], "announcement_id": "1437534", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:12Z", "company": "XSpray Pharma AB", "title": "Xspray Pharma publicerar Årsredovisning 2025", "category": "Bokslut och Verksamhetsberättelse", "date": "2026-03-26", "language": "sv", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "period": "2025-annual", "report_key": "2025:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=bbbb21defe00d4e64bb9bb66ddaf18d7d&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-annual\\release.txt", "attachments": [ { "label": "20260326 Xspray Pharma Arsredovisning 2025 Sv.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae01aee44e2723ff4457afdfae84de95c", "final_url": "https://attachment.news.eu.nasdaq.com/ae01aee44e2723ff4457afdfae84de95c", "filename": "20260326_Xspray_Pharma_Arsredovisning_2025_Sv.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-annual\\20260326_Xspray_Pharma_Arsredovisning_2025_Sv.pdf", "content_type": "application/pdf", "size": 6395534, "sha256": "2f45693c0c8e592933453650e9e5f992a05d12a66cc8101993adab71c53e431e", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-annual\\20260326_Xspray_Pharma_Arsredovisning_2025_Sv.pdf", "filename": "20260326_Xspray_Pharma_Arsredovisning_2025_Sv.pdf", "extension": ".pdf", "size": 6395534, "sha256": "2f45693c0c8e592933453650e9e5f992a05d12a66cc8101993adab71c53e431e", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\20260326_Xspray_Pharma_Arsredovisning_2025_Sv\\20260326_Xspray_Pharma_Arsredovisning_2025_Sv.txt", "text_chars": 266519, "metadata": { "page_count": 90, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-annual\\extracted\\20260326_Xspray_Pharma_Arsredovisning_2025_Sv\\20260326_Xspray_Pharma_Arsredovisning_2025_Sv.extraction.json" } } ], "announcement_id": "1429042", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:14Z", "company": "XSpray Pharma AB", "title": "Delårsrapport fjärde kvartalet 2025", "category": "Bokslutskommuniké", "date": "2026-02-12", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "period": "2025-q4", "report_key": "2025:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=b210eed9d93a4d30bfee43bb21d2dfa36&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q4\\release.txt", "attachments": [ { "label": "20260212 Xspray Pharma Q4 2025 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a2085b761e4cf1e849faa1eb4bbbeaa26", "final_url": "https://attachment.news.eu.nasdaq.com/a2085b761e4cf1e849faa1eb4bbbeaa26", "filename": "20260212_Xspray_Pharma_Q4_2025_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q4\\20260212_Xspray_Pharma_Q4_2025_SWE.pdf", "content_type": "application/pdf", "size": 467624, "sha256": "2d4e02ef3a6c68654bd187d34c08d60d376f55836f554aae4d8fd660856b7645", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q4\\20260212_Xspray_Pharma_Q4_2025_SWE.pdf", "filename": "20260212_Xspray_Pharma_Q4_2025_SWE.pdf", "extension": ".pdf", "size": 467624, "sha256": "2d4e02ef3a6c68654bd187d34c08d60d376f55836f554aae4d8fd660856b7645", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q4\\extracted\\20260212_Xspray_Pharma_Q4_2025_SWE\\20260212_Xspray_Pharma_Q4_2025_SWE.txt", "text_chars": 42171, "metadata": { "page_count": 25, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q4\\extracted\\20260212_Xspray_Pharma_Q4_2025_SWE\\20260212_Xspray_Pharma_Q4_2025_SWE.extraction.json" } } ], "announcement_id": "1419706", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:20Z", "company": "XSpray Pharma AB", "title": "Delårsrapport tredje kvartalet 2025", "category": "Interimsrapport", "date": "2025-11-05", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "period": "2025-q3", "report_key": "2025:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b7f3d8999af9843718ca8f465017f4459&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q3\\release.txt", "attachments": [ { "label": "20251105 Xspray Q3 2025 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a2973552cc28b15c2dfd57999d37e8ebe", "final_url": "https://attachment.news.eu.nasdaq.com/a2973552cc28b15c2dfd57999d37e8ebe", "filename": "20251105_Xspray_Q3_2025_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q3\\20251105_Xspray_Q3_2025_SWE.pdf", "content_type": "application/pdf", "size": 469536, "sha256": "8e1bca1d6c9eca51bf5afc23f5f4699d6aebafa0fde8c9ff5a2674ae28d8cd02", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q3\\20251105_Xspray_Q3_2025_SWE.pdf", "filename": "20251105_Xspray_Q3_2025_SWE.pdf", "extension": ".pdf", "size": 469536, "sha256": "8e1bca1d6c9eca51bf5afc23f5f4699d6aebafa0fde8c9ff5a2674ae28d8cd02", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q3\\extracted\\20251105_Xspray_Q3_2025_SWE\\20251105_Xspray_Q3_2025_SWE.txt", "text_chars": 49592, "metadata": { "page_count": 26, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q3\\extracted\\20251105_Xspray_Q3_2025_SWE\\20251105_Xspray_Q3_2025_SWE.extraction.json" } } ], "announcement_id": "1398739", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:26Z", "company": "XSpray Pharma AB", "title": "Delårsrapport andra kvartalet 2025", "category": "Halvårsrapport", "date": "2025-08-15", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "period": "2025-q2", "report_key": "2025:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b0d221895a433d699d9e51fac6f6ec0ad&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q2\\release.txt", "attachments": [ { "label": "20250815 Q2 2025 Xspray Pharma Sv.pdf", "url": "https://attachment.news.eu.nasdaq.com/a00d7f6790743fd3f21c1481d099647e3", "final_url": "https://attachment.news.eu.nasdaq.com/a00d7f6790743fd3f21c1481d099647e3", "filename": "20250815_Q2_2025_Xspray_Pharma_Sv.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q2\\20250815_Q2_2025_Xspray_Pharma_Sv.pdf", "content_type": "application/pdf", "size": 1042717, "sha256": "22ade9dbe1298fd5338335e2aa5165d910c5593b240977b15393bf153ae7bc49", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q2\\20250815_Q2_2025_Xspray_Pharma_Sv.pdf", "filename": "20250815_Q2_2025_Xspray_Pharma_Sv.pdf", "extension": ".pdf", "size": 1042717, "sha256": "22ade9dbe1298fd5338335e2aa5165d910c5593b240977b15393bf153ae7bc49", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q2\\extracted\\20250815_Q2_2025_Xspray_Pharma_Sv\\20250815_Q2_2025_Xspray_Pharma_Sv.txt", "text_chars": 44959, "metadata": { "page_count": 25, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q2\\extracted\\20250815_Q2_2025_Xspray_Pharma_Sv\\20250815_Q2_2025_Xspray_Pharma_Sv.extraction.json" } } ], "announcement_id": "1383472", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:31Z", "company": "XSpray Pharma AB", "title": "Delårsrapport första kvartalet 2025", "category": "Interimsrapport", "date": "2025-05-07", "language": "sv", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "period": "2025-q1", "report_key": "2025:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b84be54ffb099e395070137f85e4f50fd&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q1\\release.txt", "attachments": [ { "label": "20250507 Xspray Pharma Q1 2025 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae59b311919077480cf5001cb869af7bb", "final_url": "https://attachment.news.eu.nasdaq.com/ae59b311919077480cf5001cb869af7bb", "filename": "20250507_Xspray_Pharma_Q1_2025_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q1\\20250507_Xspray_Pharma_Q1_2025_SWE.pdf", "content_type": "application/pdf", "size": 923007, "sha256": "e039b8905a6bcd363ac7fccae066eb64a978314a6a7a04845265de116a2e6093", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q1\\20250507_Xspray_Pharma_Q1_2025_SWE.pdf", "filename": "20250507_Xspray_Pharma_Q1_2025_SWE.pdf", "extension": ".pdf", "size": 923007, "sha256": "e039b8905a6bcd363ac7fccae066eb64a978314a6a7a04845265de116a2e6093", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q1\\extracted\\20250507_Xspray_Pharma_Q1_2025_SWE\\20250507_Xspray_Pharma_Q1_2025_SWE.txt", "text_chars": 37760, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2025-q1\\extracted\\20250507_Xspray_Pharma_Q1_2025_SWE\\20250507_Xspray_Pharma_Q1_2025_SWE.extraction.json" } } ], "announcement_id": "1361333", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:38Z", "company": "XSpray Pharma AB", "title": "Xspray Pharma publicerar årsredovisning för 2024", "category": "Bokslut och Verksamhetsberättelse", "date": "2025-03-27", "language": "sv", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "period": "2024-annual", "report_key": "2024:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=b90ee4f2d0d123f6356c6cbf26c0e28d8&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-annual\\release.txt", "attachments": [ { "label": "20250327 Xspray Arsredovisning 2024 Sv.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad983d0ddc1684674f58fc36133dc6082", "final_url": "https://attachment.news.eu.nasdaq.com/ad983d0ddc1684674f58fc36133dc6082", "filename": "20250327_Xspray_Arsredovisning_2024_Sv.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-annual\\20250327_Xspray_Arsredovisning_2024_Sv.pdf", "content_type": "application/pdf", "size": 13775833, "sha256": "706f93b3b3ba44a8ef5dd4c2ba85689608b03cf91c8b2f742cad483acedb41d3", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-annual\\20250327_Xspray_Arsredovisning_2024_Sv.pdf", "filename": "20250327_Xspray_Arsredovisning_2024_Sv.pdf", "extension": ".pdf", "size": 13775833, "sha256": "706f93b3b3ba44a8ef5dd4c2ba85689608b03cf91c8b2f742cad483acedb41d3", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-annual\\extracted\\20250327_Xspray_Arsredovisning_2024_Sv\\20250327_Xspray_Arsredovisning_2024_Sv.txt", "text_chars": 248500, "metadata": { "page_count": 90, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-annual\\extracted\\20250327_Xspray_Arsredovisning_2024_Sv\\20250327_Xspray_Arsredovisning_2024_Sv.extraction.json" } } ], "announcement_id": "1351564", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:42Z", "company": "XSpray Pharma AB", "title": "Delårsrapport fjärde kvartalet 2024", "category": "Bokslutskommuniké", "date": "2025-02-12", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2024, "quarter": "q4", "period": "2024-q4", "report_key": "2024:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=bbe94d8780b1a190c213beec15aad7e2e&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q4\\release.txt", "attachments": [ { "label": "20250212 Xspray Pharma Q4 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ac0d2e0c82f48999bc87eaef7f68bc17f", "final_url": "https://attachment.news.eu.nasdaq.com/ac0d2e0c82f48999bc87eaef7f68bc17f", "filename": "20250212_Xspray_Pharma_Q4_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q4\\20250212_Xspray_Pharma_Q4_2024_SWE.pdf", "content_type": "application/pdf", "size": 1039108, "sha256": "ce72ee6a9107d2a9d2c5632fcd774ec9a32049f529807ef35e7cb0df90ef5858", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q4\\20250212_Xspray_Pharma_Q4_2024_SWE.pdf", "filename": "20250212_Xspray_Pharma_Q4_2024_SWE.pdf", "extension": ".pdf", "size": 1039108, "sha256": "ce72ee6a9107d2a9d2c5632fcd774ec9a32049f529807ef35e7cb0df90ef5858", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q4\\extracted\\20250212_Xspray_Pharma_Q4_2024_SWE\\20250212_Xspray_Pharma_Q4_2024_SWE.txt", "text_chars": 42996, "metadata": { "page_count": 25, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q4\\extracted\\20250212_Xspray_Pharma_Q4_2024_SWE\\20250212_Xspray_Pharma_Q4_2024_SWE.extraction.json" } } ], "announcement_id": "1342324", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:46Z", "company": "XSpray Pharma AB", "title": "Delårsrapport tredje kvartalet 2024", "category": "Interimsrapport", "date": "2024-11-06", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "period": "2024-q3", "report_key": "2024:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=bbe17d0868d4a7dd5c97b7cea4ed2b6d0&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q3\\release.txt", "attachments": [ { "label": "20241106 Xspray Q3 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a95f135cd65eb2de4cd562a7765280325", "final_url": "https://attachment.news.eu.nasdaq.com/a95f135cd65eb2de4cd562a7765280325", "filename": "20241106_Xspray_Q3_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q3\\20241106_Xspray_Q3_2024_SWE.pdf", "content_type": "application/pdf", "size": 1085430, "sha256": "999635d16ff274d2a309dfbbb1c11fd1df287aa8e5acbe8a8eb820e96aa4f6be", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q3\\20241106_Xspray_Q3_2024_SWE.pdf", "filename": "20241106_Xspray_Q3_2024_SWE.pdf", "extension": ".pdf", "size": 1085430, "sha256": "999635d16ff274d2a309dfbbb1c11fd1df287aa8e5acbe8a8eb820e96aa4f6be", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q3\\extracted\\20241106_Xspray_Q3_2024_SWE\\20241106_Xspray_Q3_2024_SWE.txt", "text_chars": 52179, "metadata": { "page_count": 26, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q3\\extracted\\20241106_Xspray_Q3_2024_SWE\\20241106_Xspray_Q3_2024_SWE.extraction.json" } } ], "announcement_id": "1325989", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:51Z", "company": "XSpray Pharma AB", "title": "Delårsrapport andra kvartalet 2024", "category": "Halvårsrapport", "date": "2024-08-07", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "period": "2024-q2", "report_key": "2024:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=bee040ef17a0ba896880fbca03f7fab90&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q2\\release.txt", "attachments": [ { "label": "20240807 Xspray Q2 2024 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad0827b50527699a23f334ff8952dd66d", "final_url": "https://attachment.news.eu.nasdaq.com/ad0827b50527699a23f334ff8952dd66d", "filename": "20240807_Xspray_Q2_2024_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q2\\20240807_Xspray_Q2_2024_SWE.pdf", "content_type": "application/pdf", "size": 732966, "sha256": "a6a3cf1b14ed8c151100b86619225f73bc2624eb47761beb82eb8c10bd3e764c", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q2\\20240807_Xspray_Q2_2024_SWE.pdf", "filename": "20240807_Xspray_Q2_2024_SWE.pdf", "extension": ".pdf", "size": 732966, "sha256": "a6a3cf1b14ed8c151100b86619225f73bc2624eb47761beb82eb8c10bd3e764c", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q2\\extracted\\20240807_Xspray_Q2_2024_SWE\\20240807_Xspray_Q2_2024_SWE.txt", "text_chars": 44933, "metadata": { "page_count": 25, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q2\\extracted\\20240807_Xspray_Q2_2024_SWE\\20240807_Xspray_Q2_2024_SWE.extraction.json" } } ], "announcement_id": "1309631", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:46:58Z", "company": "XSpray Pharma AB", "title": "Delårsrapport första kvartalet 2024", "category": "Interimsrapport", "date": "2024-05-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q1", "period": "2024-q1", "report_key": "2024:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=bf6047f3a3d8dda0ea3f215bbc18f12c6&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q1\\release.txt", "attachments": [ { "label": "20240508 Xspray Pharma Q1 2024 Rapport Sv.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae427f3bc7ac305abb40e57c5e2b0d750", "final_url": "https://attachment.news.eu.nasdaq.com/ae427f3bc7ac305abb40e57c5e2b0d750", "filename": "20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q1\\20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.pdf", "content_type": "application/pdf", "size": 1428215, "sha256": "17e047cbc2fa02bba9510944f39e37cb24867cbfeb9a05888688fc7818f606fb", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q1\\20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.pdf", "filename": "20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.pdf", "extension": ".pdf", "size": 1428215, "sha256": "17e047cbc2fa02bba9510944f39e37cb24867cbfeb9a05888688fc7818f606fb", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q1\\extracted\\20240508_Xspray_Pharma_Q1_2024_Rapport_Sv\\20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.txt", "text_chars": 40316, "metadata": { "page_count": 24, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2024-q1\\extracted\\20240508_Xspray_Pharma_Q1_2024_Rapport_Sv\\20240508_Xspray_Pharma_Q1_2024_Rapport_Sv.extraction.json" } } ], "announcement_id": "1294324", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:47:05Z", "company": "XSpray Pharma AB", "title": "Xspray Pharma publicerar årsredovisning 2023", "category": "Bokslut och Verksamhetsberättelse", "date": "2024-03-27", "language": "sv", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "period": "2023-annual", "report_key": "2023:annual", "release_url": "https://view.news.eu.nasdaq.com/view?id=ba29714bc618f03e7f4c72f0ac1adc1bf&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-annual\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-annual\\release.txt", "attachments": [ { "label": "20240327 Xspray Pharma Arsredovisning 2023 Sv.pdf", "url": "https://attachment.news.eu.nasdaq.com/ad9fd8db8f5736fc5fabd195c1072b922", "final_url": "https://attachment.news.eu.nasdaq.com/ad9fd8db8f5736fc5fabd195c1072b922", "filename": "20240327_Xspray_Pharma_Arsredovisning_2023_Sv.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-annual\\20240327_Xspray_Pharma_Arsredovisning_2023_Sv.pdf", "content_type": "application/pdf", "size": 17520774, "sha256": "57da7d7a02646ea2eefe2f61c826a6b3e6635b9ba76fc6c95a33291ce513d650", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-annual\\20240327_Xspray_Pharma_Arsredovisning_2023_Sv.pdf", "filename": "20240327_Xspray_Pharma_Arsredovisning_2023_Sv.pdf", "extension": ".pdf", "size": 17520774, "sha256": "57da7d7a02646ea2eefe2f61c826a6b3e6635b9ba76fc6c95a33291ce513d650", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-annual\\extracted\\20240327_Xspray_Pharma_Arsredovisning_2023_Sv\\20240327_Xspray_Pharma_Arsredovisning_2023_Sv.txt", "text_chars": 247137, "metadata": { "page_count": 90, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-annual\\extracted\\20240327_Xspray_Pharma_Arsredovisning_2023_Sv\\20240327_Xspray_Pharma_Arsredovisning_2023_Sv.extraction.json" } } ], "announcement_id": "1284149", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:47:07Z", "company": "XSpray Pharma AB", "title": "Delårsrapport fjärde kvartalet 2023", "category": "Bokslutskommuniké", "date": "2024-02-14", "language": "sv", "report_type": "year-end-report", "fiscal_year": 2023, "quarter": "q4", "period": "2023-q4", "report_key": "2023:q4", "release_url": "https://view.news.eu.nasdaq.com/view?id=bd16eef133f40bb919111be18d697058d&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q4\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q4\\release.txt", "attachments": [ { "label": "2024 02 14 XsprayPharma Q4 Rapport SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a140a716efe18f1eb185d46b153d16935", "final_url": "https://attachment.news.eu.nasdaq.com/a140a716efe18f1eb185d46b153d16935", "filename": "2024_02_14_XsprayPharma_Q4_Rapport_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q4\\2024_02_14_XsprayPharma_Q4_Rapport_SWE.pdf", "content_type": "application/pdf", "size": 709072, "sha256": "ee901f87fdb52b52194f01ea087543f9f618c13c5bb010140dcb8d328b0d60b3", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q4\\2024_02_14_XsprayPharma_Q4_Rapport_SWE.pdf", "filename": "2024_02_14_XsprayPharma_Q4_Rapport_SWE.pdf", "extension": ".pdf", "size": 709072, "sha256": "ee901f87fdb52b52194f01ea087543f9f618c13c5bb010140dcb8d328b0d60b3", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q4\\extracted\\2024_02_14_XsprayPharma_Q4_Rapport_SWE\\2024_02_14_XsprayPharma_Q4_Rapport_SWE.txt", "text_chars": 45285, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q4\\extracted\\2024_02_14_XsprayPharma_Q4_Rapport_SWE\\2024_02_14_XsprayPharma_Q4_Rapport_SWE.extraction.json" } } ], "announcement_id": "1274600", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:47:13Z", "company": "XSpray Pharma AB", "title": "Delårsrapport tredje kvartalet 2023", "category": "Interimsrapport", "date": "2023-11-08", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "period": "2023-q3", "report_key": "2023:q3", "release_url": "https://view.news.eu.nasdaq.com/view?id=b0e99301c43a160e104a2d8e31cc05d7a&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q3\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q3\\release.txt", "attachments": [ { "label": "20231108 Xspray Pharma Q3 2023 Rapport SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/a92ea5449e715c9e54884b6eb64ddabd4", "final_url": "https://attachment.news.eu.nasdaq.com/a92ea5449e715c9e54884b6eb64ddabd4", "filename": "20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q3\\20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.pdf", "content_type": "application/pdf", "size": 690017, "sha256": "f61c4d7618408aa09df8cd67ed266e4d4648ce31270bddc9fda8960fe66d43e7", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q3\\20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.pdf", "filename": "20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.pdf", "extension": ".pdf", "size": 690017, "sha256": "f61c4d7618408aa09df8cd67ed266e4d4648ce31270bddc9fda8960fe66d43e7", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\20231108_Xspray_Pharma_Q3_2023_Rapport_SWE\\20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.txt", "text_chars": 48050, "metadata": { "page_count": 23, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q3\\extracted\\20231108_Xspray_Pharma_Q3_2023_Rapport_SWE\\20231108_Xspray_Pharma_Q3_2023_Rapport_SWE.extraction.json" } } ], "announcement_id": "1257884", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:47:17Z", "company": "XSpray Pharma AB", "title": "Delårsrapport andra kvartalet 2023", "category": "Halvårsrapport", "date": "2023-08-02", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "period": "2023-q2", "report_key": "2023:q2", "release_url": "https://view.news.eu.nasdaq.com/view?id=b65b2da9c0cea0909d3fcf2e0af50fd5c&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q2\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q2\\release.txt", "attachments": [ { "label": "Xspray Q2 Rapport SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/ae3558d64f63ccbf7c7ada0c7ccbf2557", "final_url": "https://attachment.news.eu.nasdaq.com/ae3558d64f63ccbf7c7ada0c7ccbf2557", "filename": "Xspray_Q2_Rapport_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q2\\Xspray_Q2_Rapport_SWE.pdf", "content_type": "application/pdf", "size": 717488, "sha256": "46f070043e9ca848d42fa0b69b0b0ce8d442f436ec7f568c31599d110c2237d7", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q2\\Xspray_Q2_Rapport_SWE.pdf", "filename": "Xspray_Q2_Rapport_SWE.pdf", "extension": ".pdf", "size": 717488, "sha256": "46f070043e9ca848d42fa0b69b0b0ce8d442f436ec7f568c31599d110c2237d7", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q2\\extracted\\Xspray_Q2_Rapport_SWE\\Xspray_Q2_Rapport_SWE.txt", "text_chars": 43237, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q2\\extracted\\Xspray_Q2_Rapport_SWE\\Xspray_Q2_Rapport_SWE.extraction.json" } } ], "announcement_id": "1240826", "status": "retrieved" }, { "source": "Nasdaq Nordic", "fetcher_build": "2026-08-04-fresh-local-files-v5.0.2", "retrieved_at": "2026-08-07T08:47:23Z", "company": "XSpray Pharma AB", "title": "Delårsrapport första kvartalet 2023", "category": "Interimsrapport", "date": "2023-05-04", "language": "sv", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "period": "2023-q1", "report_key": "2023:q1", "release_url": "https://view.news.eu.nasdaq.com/view?id=b915d08ed3d340c5c2238ff2e30b5184c&lang=sv&src=listed", "release_html_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q1\\release.html", "release_text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q1\\release.txt", "attachments": [ { "label": "20230504 Xspray Pharma Q1 2023 SWE.pdf", "url": "https://attachment.news.eu.nasdaq.com/abca29c48cc1571e3bd7eaf6682e27ba1", "final_url": "https://attachment.news.eu.nasdaq.com/abca29c48cc1571e3bd7eaf6682e27ba1", "filename": "20230504_Xspray_Pharma_Q1_2023_SWE.pdf", "local_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q1\\20230504_Xspray_Pharma_Q1_2023_SWE.pdf", "content_type": "application/pdf", "size": 787724, "sha256": "5233c3df9bbc521cb373ca446c0c759309e5d7b037b0a536b78cbfd48ca49c6f", "extraction": { "source_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q1\\20230504_Xspray_Pharma_Q1_2023_SWE.pdf", "filename": "20230504_Xspray_Pharma_Q1_2023_SWE.pdf", "extension": ".pdf", "size": 787724, "sha256": "5233c3df9bbc521cb373ca446c0c759309e5d7b037b0a536b78cbfd48ca49c6f", "status": "extracted", "text_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q1\\extracted\\20230504_Xspray_Pharma_Q1_2023_SWE\\20230504_Xspray_Pharma_Q1_2023_SWE.txt", "text_chars": 41483, "metadata": { "page_count": 22, "empty_pages": 0, "encrypted": false }, "children": [], "warnings": [], "manifest_path": "D:\\Web\\aktieanalys\\data\\xspray-pharma\\nasdaq-reports\\reports\\2023-q1\\extracted\\20230504_Xspray_Pharma_Q1_2023_SWE\\20230504_Xspray_Pharma_Q1_2023_SWE.extraction.json" } } ], "announcement_id": "1225326", "status": "retrieved" } ], "attempts": [ { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "12b9d8a739024345f74adaf2fb2ef922fbafb80c5f1e37b090063e2ca2c19a52" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 100, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "3f36eea20d7b8c739e86ca7f3fa9662f82fbc818f7632a9c03bbddf1ed3a8a77" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 200, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 71, "new_rows": 71, "total_count": null, "from_cache": false, "body_sha256": "f8309c36682edc20930be5ef165c68f46dd87bfe1dceed49ab21401444ee3b7e" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=271&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "sv", "start": 271, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "9054ec752522803fc9eedece37383755d89dd1223c71a24d4412e590d0a743bf" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 0, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 5, "new_rows": 5, "total_count": null, "from_cache": false, "body_sha256": "5a0a82caf15a0941ef62617fb87d6da007aba850dc38c3f38bf9fa6f7f5e3004" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=sv&language=sv&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=5&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "sv", "start": 5, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "d97ee824ab5793095b25a383238d191f6e98476d65197a4c886f360e00a0680f" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "be1219f9ec7dcbf2c7ebef9f3812f19ad8ad73ea14ed721a09961271daa3b044" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=100&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 100, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 100, "new_rows": 100, "total_count": null, "from_cache": false, "body_sha256": "75d4c8899e29b1e686ca3b0550f8cdc28bb5cdf7214decb6c0f58a9dc46b0993" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=200&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 200, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 46, "new_rows": 46, "total_count": null, "from_cache": false, "body_sha256": "00132d71cb33ee7fa5b709acdf6e600456a26c93abcf8db624d6e72d9e8b3dca" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicMainMarkets&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=246&dir=DESC", "status": 200, "scope": "NordicMainMarkets", "language": "en", "start": 246, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "5c9ae7ea3b6be02b6477658f3a7ce5885f8e7d2e012fb96534eed1a2fc954161" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=0&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 0, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 2, "new_rows": 2, "total_count": null, "from_cache": false, "body_sha256": "27333166d0f49296dd2c6e66f052e661d06e46de50cfe6975538eeb69b717ae4" }, { "url": "https://api.news.eu.nasdaq.com/news/query.action?type=handleResponse&showAttachments=true&showCnsSpecific=true&showCompany=true&countResults=true&freeText=XSpray+Pharma&company=&market=&cnscategory=&fromDate=2023-01-01&toDate=&globalGroup=exchangeNotice&globalName=NordicFirstNorth&displayLanguage=en&language=en&timeZone=CET&dateMask=yyyy-MM-dd+HH%3Amm%3Ass&limit=100&start=2&dir=DESC", "status": 200, "scope": "NordicFirstNorth", "language": "en", "start": 2, "pagination": "row-offset", "query_text": "XSpray Pharma", "from_date": "2023-01-01", "to_date": "", "cache_tag": "broad", "rows": 0, "new_rows": 0, "total_count": null, "from_cache": false, "body_sha256": "8cf81a327a3a8b325adfd784ef5b23173c052fd172113cb13a000ad4e443c411" } ], "identity": { "slug": "", "instrument_id": "TX2489842", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/xspray?id=TX2489842" }, "transport": "ordinary-http", "browser_used": false, "query_text": "XSpray Pharma", "retrieved_at": "2026-08-07T08:47:23Z" }